Your browser doesn't support javascript.
loading
A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults.
Sheehan, Sharon; Harris, Stephanie A; Satti, Iman; Hokey, David A; Dheenadhayalan, Veerabadran; Stockdale, Lisa; Manjaly Thomas, Zita-Rose; Minhinnick, Alice; Wilkie, Morven; Vermaak, Samantha; Meyer, Joel; O'Shea, Matthew K; Pau, Maria Grazia; Versteege, Isabella; Douoguih, Macaya; Hendriks, Jenny; Sadoff, Jerald; Landry, Bernard; Moss, Paul; McShane, Helen.
Affiliation
  • Sheehan S; The Jenner Institute, University of Oxford, Oxford, OX3 7DQ, United Kingdom.
  • Harris SA; The Jenner Institute, University of Oxford, Oxford, OX3 7DQ, United Kingdom.
  • Satti I; The Jenner Institute, University of Oxford, Oxford, OX3 7DQ, United Kingdom.
  • Hokey DA; Aeras Global TB Vaccine Foundation, Rockville, MD, United States of America.
  • Dheenadhayalan V; Aeras Global TB Vaccine Foundation, Rockville, MD, United States of America.
  • Stockdale L; The Jenner Institute, University of Oxford, Oxford, OX3 7DQ, United Kingdom.
  • Manjaly Thomas ZR; The Jenner Institute, University of Oxford, Oxford, OX3 7DQ, United Kingdom.
  • Minhinnick A; The Jenner Institute, University of Oxford, Oxford, OX3 7DQ, United Kingdom.
  • Wilkie M; The Jenner Institute, University of Oxford, Oxford, OX3 7DQ, United Kingdom.
  • Vermaak S; The Jenner Institute, University of Oxford, Oxford, OX3 7DQ, United Kingdom.
  • Meyer J; The Jenner Institute, University of Oxford, Oxford, OX3 7DQ, United Kingdom.
  • O'Shea MK; The Jenner Institute, University of Oxford, Oxford, OX3 7DQ, United Kingdom.
  • Pau MG; Janssen Infectious Diseases and Vaccines (formerly Crucell), Leiden, The Netherlands.
  • Versteege I; Janssen Infectious Diseases and Vaccines (formerly Crucell), Leiden, The Netherlands.
  • Douoguih M; Janssen Infectious Diseases and Vaccines (formerly Crucell), Leiden, The Netherlands.
  • Hendriks J; Janssen Infectious Diseases and Vaccines (formerly Crucell), Leiden, The Netherlands.
  • Sadoff J; Janssen Infectious Diseases and Vaccines (formerly Crucell), Leiden, The Netherlands.
  • Landry B; Aeras Global TB Vaccine Foundation, Rockville, MD, United States of America.
  • Moss P; School of Cancer Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, United Kingdom.
  • McShane H; The Jenner Institute, University of Oxford, Oxford, OX3 7DQ, United Kingdom.
PLoS One ; 10(11): e0141687, 2015.
Article in En | MEDLINE | ID: mdl-26529238
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Adenoviridae / Immunization, Secondary / Tuberculosis Vaccines / Mycobacterium bovis / Mycobacterium tuberculosis / Antigens, Bacterial Limits: Adolescent / Adult / Female / Humans / Male / Middle aged Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2015 Document type: Article Affiliation country: Reino Unido Country of publication: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Adenoviridae / Immunization, Secondary / Tuberculosis Vaccines / Mycobacterium bovis / Mycobacterium tuberculosis / Antigens, Bacterial Limits: Adolescent / Adult / Female / Humans / Male / Middle aged Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2015 Document type: Article Affiliation country: Reino Unido Country of publication: Estados Unidos